

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 26th June, 2020

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400 001

Script ID: 506365

SUBJECT: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31/03/2020, DECLARATION, FORM 'A' AND AUDITORS REPORT IN BOARD MEETING HELD ON 26TH JUNE, 2020

Dear Sirs,

Pursuant to Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on Friday, 26th June, 2020 at 04:00 P.M. at Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai – 400 001 approved the following:

1. Standalone Financial Results for the quarter and year ended 31st March, 2020
2. Form 'A' for the year ended 31st March, 2020
3. Auditors Report on Standalone Financial Results for the year ended 31st March, 2020
4. Declaration regarding Audit Report with unmodified opinion

The Company will not be publishing these Financial Results in the newspaper under Regulation 47 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, in view of SEBI Circular dated 12th May, 2020 vide circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 and on account of the lock-down restrictions imposed by the Government of India.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

Ashok Somani

ASHOK SOMANI
DIRECTOR
(DIN - 03063364)



Place: Mumbai

CHEMO PHARMA LABORATORIES LIMITED






Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

FORM A as per Regulation 33 (3)(d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

1.	Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2.	Annual Financial Statements for the year ended	31 st March, 2020
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	 
	• Audit Committee Chairman – Balkishan Lohia	



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001






• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

DECLARATION

Declaration regarding Un-Modified Audit Report in respect Standalone Financial Statements for the Financial Year 2019-2020 under SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016

We hereby declare that we have submitted the Audit Reports in respect of Standalone Financial Statements for the year 2019-2020, along with the Financial Results on 26th June, 2020. We hereby confirm that auditors have expressed an Un-modified Opinion in their Audit Reports on Standalone Financial Statements

1.	Name of the Company:	CHEMO PHARMA LABORATORIES LIMITED
2.	Annual Financial Statements for the year ended	31 st March, 2020
3.	Type of Audit observation	Un-Qualified
4.	Frequency of observation	-
5.	To be signed by-	
	• CEO – SHREENIWAS SOMANI	
	• CFO – ASHOK SOMANI	
	• Auditor of the Company – VMD & Co.	 
	• Audit Committee Chairman – Balkishan Lohia	





AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To the Board of Directors of **CHEMO PHARMA LABORATORIES LIMITED**

We have audited the quarterly financial results of ChemoPharma Laboratories Limited for the quarter ended March 31, 2020 and the year to date results for the period April 1, 2019 to March 31, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We have conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2020 as well as the year to date results for the period from April 1, 2019 to March 31, 2020.

For VMD & Co.
Chartered Accountants
FRN: 125002W

CA Amit Ganpule
Partner
MRN: 114222
Place : Mumbai
Date: June 26, 2020
UDIN:

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 • Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31ST MARCH, 2020

Sr. No.	Particulars	Quarter Ended			Year Ended	
		31 st March 2020	31 st Dec., 2019	31st March 2019	31 st March 2019	31 st March 2020
		Un-audited	Un-audited	Un-audited	Audited	Audited
I	Revenue from Operations	-	-	-	-	-
II	Other Income	2,859	1,499	4,266	8,225	9,967
III	Total Revenue (I + II)	2,859	1,499	4,266	8,225	9,967
IV	Expenses					
	(1) Cost Materials consumed	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-
	(4) Finance Costs	-	-	-	-	-
	(5) Employee Benefits Expenses	404	574	526	2,218	1,813
	(6) Depreciation and Amortisation Expenses	231	-	-	47	231
	(7) Administrative and Other Expenses	1,253	242	854	3,414	2,982
	i) Professional Charges	-	-	-	-	-
	ii) Share Registry Expenses	-	-	-	-	-
	iii) Annual Listing Fees	-	-	-	-	-
	iv) Postal Charges	-	-	-	-	-
	Total Expenses	1,888	816	1,380	5,679	5,026
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	971	683	2,886	2,546	4,941
VI	Exceptional Items	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	971	683	2,886	2,546	4,941
VIII	Extra Ordinary Items	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	971	683	2,886	2,546	4,941
X	Tax Expenses					
	(1) Current Tax	760	-	460	460	760
	(2) Tax Adjusted Previous Year	30	-	-	23	30
	(3) Deferred Tax	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	181	683	2,426	2,063	4,151
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	181	683	2,426	2,063	4,151
XVI	Other Comprehensive Income					
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	181	683	2,426	2,063	4,151
XVIII	Earnings per Share :					
	Basic (1)	0.12	0.46	1.62	1.38	2.77
	(2) Diluted					

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Standalone Audited Financial Results for the Quarter and Year Ended 31.03.2020 have been reviewed by the Audit Committee in their Meeting held on 26.06.2020 and approved by the Board of Directors of its Meeting held on 26.06.2020. The Audit Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is not having any Subsidiary Company.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai
Date : 26th June, 2020



For Chemo Pharma Laboratories Limited

Ashok Somani

Ashok Somani
Director
DIN : 03063364

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 31ST MARCH, 2020

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 31.03.2020 Audited	As at 31.03.2019 Audited
1	ASSETS		
	Non-Current Assets		
	(A) Property, Plant and Equipement	747	30
	(B) Financial Assets		
	(i) Investment	237	369
	(ii) Loans	19,568	18,417
	<i>Total Non-current Assets</i>	20,552	18,816
	Current Assets		
	(i) Cash & Cash Equivalents	8,084	4,662
	(ii) Fixed Deposits	80,000	80,732
	(iii) Other Current Assets	1,021	732
	<i>Total Current Assets</i>	89,105	85,394
	TOTAL ASSETS	109,657	104,210
2	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity	92,447	88,296
	<i>Total Equity</i>	107,447	103,296
	Liabilities		
	Non- Current Liabilities	-	-
	Current Liabilities		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,450	1,259
	(iii) Provisions	760	(343)
	<i>Total Current Liabilities</i>	2,210	914
	TOTAL EQUITY AND LIABILITIES	109,657	104,210

By Order of the Board
For Chemo Pharma Laboratories Limited

Ashok Somani

ASHOK SOMANI
DIRECTOR
DIN : 03063364

Place : Mumbai
Date : 26th June, 2020



CHEMO PHARMA LABORATORIES LIMITED


Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2020

(Rs. in Thousands)

PARTICULARS	STANDALONE	
	AUDITED QUARTER ENDED 31.03.2020	AUDITED YEAR ENDED 31.03.2020
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	181	4,151
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	181	4,151

For Chemo Pharma Laboratories Ltd.



Ashok Somani
Director
DIN : 03063364

Mumbai
Date: 26th June, 2020



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH, 2020

PARTICULARS	31st March 2020 (in Rupees)	31st March 2019 (in Rupees)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items	4,941,336	2,546,087
Adjustement for		
Depreciation	231,274	47,001
Dividend received	(5,658)	(1,326)
Interest received	(9,961,933)	(8,042,768)
Operating profit before working capital changes	(4,794,981)	(5,451,005)
Adjustement for		
Increase (Decrease) in other Current Liabilities	1,295,411	(417,311)
Decrease (increase) in Current Assets	54,711,165	(46,896,637)
Increase in loans given	(1,150,200)	(1,533,600)
Increase in Fixed Assets	(948,565)	(56,522)
Cash Generated From Operation	53,907,811	(48,904,070)
Taxes Paid	(789,788)	(483,183)
A. Cash Flow From Operating Activities	48,323,042	(54,838,258)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Dividend received	5,658	1,326
Interest received	9,961,933	8,042,768
Decrease in Investment	131,916	(181,322)
Cash Flow From Investing Activities	10,099,507	7,862,772
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest Paid	-	-
Cash Flow From Financing Activities	-	-
Net increase/(decrease) in cash and cash Equivalents	58,422,549	(46,975,486)
Opening balance of Cash and Cash Equivalents	29,661,539	76,637,027
Closing Balance Of Cash and Cash Equivalents	88,084,088	29,661,539

Note:

1. The above Cash Flow Statement has been prepared under the indirect method as set out in the Ind AS-7 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

For Chemo Pharma Laboratories Limited

Place : Mumbai
Date : 26th June, 2020



Ashok Somani

Ashok Somani
Director
DIN : 03063364